acquired severe aplastic anaemia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged <= 60 years; 2. Male and female patient; 3. Severe aplastic anemia or transplansion dependant aplastic anemia by Camitta criteria; 4. Suitable fully matched sibling donor available (10/10 or 9/10 match for human leukocyte antigen); 5. The score of ECOG in this study was less than 2; 6. Patient and/or legal guardian must sign informed consent for HSCT.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled viral, bacterial, and fungal infections (progression of disease during antifungal therapy); 2. Antilymphocytic immunoglobulin severe allergy (anaphylactic shock or laryngeal edema); 3. Combined with serious heart, lung, liver or kidney disease: Left ventricular ejection fraction (LVEF) 2.0 x the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.0 x ULN; Estimated creatinine clearance 130umol/L. 4. Heart, liver, pancreas with severe iron deposition or serum ferritin> 3000 ug/ L 5. Pregnant and lactating women; 6. Men and women who do not agree to contraception during the trial period; 7. HIV seropositive; 8. Malignant tumor; 9. Prior allogeneic stem cell transplant or prior solid organ transplant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidences of acute graft-vs-host-disease (aGVHD);incidence of chronic GVHD;immune reconstitution; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sustained engraftment;TRM;Incidence of fungal infection;Incidence of CMV infection;Incidence of EBV infection;over survival; | — |
Countries
China
Contacts
hematology department of Wuhan Union Hospital